10-Year Case Study Suggests Whole-Plant Hemp May Reduce Seizure Frequency
Groundbreaking 10-Year Case Study Highlights Potential of Whole-Plant Hemp Extract for Dravet Syndrome
A newly published case report in the Journal of Chiropractic Medicine presents a decade-long observation of a pediatric patient with Dravet syndrome who experienced a notable reduction in seizure frequency while using a whole-plant cannabinoid wellness protocol. Conducted by Dr. Trent Jones and colleagues, the study followed the patient from age 7 to 16, documenting a reduction from 28 daily seizures to fewer than 10 mild monthly episodes.
Study Overview
The case, titled “Whole Plant Cannabinoid Nonpharmaceutical Treatment Protocols for a Young Male With Dravet Syndrome” (DOI: 10.1016/j.jcm.2025.09.014), explores a conservative and consistent hemp-derived phytocannabinoid approach supported by nutritional and environmental changes.
Key Findings
-
Patient diagnosed with Dravet syndrome (SCN1A mutation)
-
Whole-plant hemp extract administered at 1 mg/kg/day
-
Seizures reduced by over 90% within two weeks
-
Stabilized at 7–10 mild monthly events by age 16
-
All pharmaceuticals successfully discontinued after four years
-
No observed adverse side effects during the 10-year period
Quote From the Lead Author
“This case demonstrates the potential of whole-plant hemp formulations as a complementary approach for severe seizure disorders,” said Dr. Trent Jones, lead author and founder of Apothio, LLC. “We observed long-term stability and functional improvement without the adverse effects associated with standard pharmaceuticals.”
A Holistic Research Approach
The 10-year protocol was supervised by chiropractic and medical specialists and focused on supporting balance within the endocannabinoid system (ECS) and the microbiota-gut-brain axis (MGBA)—both key areas of interest in neurological stability and whole-system wellness.
The publication includes:
-
A detailed multi-year timeline
-
Observations on daily functioning
-
A glossary explaining cannabinoid pathways, receptor systems, and the entourage effect
About Apothio, LLC
Apothio is a biotechnology and agricultural research company dedicated to advancing plant-powered wellness through evidence-based cannabinoid science. Through collaborative work with clinicians, researchers, and universities, Apothio explores regenerative agriculture and nature-forward innovation designed to support human wellbeing.
Learn more at www.apothio.life
Media Contact
Trent Jones
Apothio, LLC
Email: drtrentjones@apothio.life